NCT05804578 Using a Blood Test to Monitor Metastatic Breast Cancer Treatment
| NCT ID | NCT05804578 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr. Christopher Mueller |
| Condition | Metastatic Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-10-19 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2023-10-19 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.
Eligibility Criteria
Inclusion Criteria -Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]
Contact & Investigator
Christopher R Mueller, Ph.D.
PRINCIPAL INVESTIGATOR
Queen's University
Frequently Asked Questions
Who can join the NCT05804578 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Metastatic Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05804578 currently recruiting?
Yes, NCT05804578 is actively recruiting participants. Contact the research team at muellerc@queensu.ca for enrollment information.
Where is the NCT05804578 trial being conducted?
This trial is being conducted at Kingston, Canada, Toronto, Canada.
Who is sponsoring the NCT05804578 clinical trial?
NCT05804578 is sponsored by Dr. Christopher Mueller. The principal investigator is Christopher R Mueller, Ph.D. at Queen's University. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.